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 4 
Abstract 
Proper regulation of cell death and the inflammatory mechanism leading to cell death is vital for 
the development and homeostasis of living organisms. Dysregulation of cell death leads to cancer, 
neurodegenerative disorders, and inflammatory conditions such as sepsis. Caspases are major players of 
cell death. In gram-negative bacteria induced sepsis, LPS directly binds to caspase-4 and 5 to induce 
pyroptosis. With the hypothesis that inhibition of caspase-4 may be required to provide protection from 
sepsis, the first goal of this research is to identify and characterize novel small molecules that inhibit 
caspase-4. Additionally, nonsteriodal anti-inflammatory drugs (NSAIDs) provide analgesic and 
antipyretic effects, but the mechanism of their adverse side effects such as the gastrointestinal bleeding 
and development of ulcers is unknown. With the hypothesis that NSAIDs mechanism may involve 
caspases, the second goal of this research is to study the effect of NSAIDs on caspases. 3700 compounds 
from the Soft Focus Protease/Kinase Library (P/K) and Prestwick Chemical Library (FDA) were screened 
against caspase-4 activity using a Caspase-Glo enzymatic activity assay. Two compounds from P/K were 
identified as promising caspase-4 specific inhibitors. FDA screen revealed that 56% of the top caspase-4 
inhibitors were NSAIDs. Further characterization of six diverse NSAIDs revealed NSAIDs are pan-
caspase inhibitors and that their IC50 values are lower than the average concentration present in blood. 
Considering that the knockout of mice-homologous caspase-4 increased susceptibility of bacterial 
infection in mice gut and knockout of caspase-1 increased tumorogenesis in mice, NSAIDs being pan-
caspase inhibitors has serious implications for NSAIDs’ side effects. This study supports the hypothesis 
that caspases may be involved in the mechanism of side effects of NSAIDs.  
 
 
 
 5 
Background 
Caspases 
Caspases are a family of cysteine proteases that are vital in programmed cell death. An 
extrinsic or intrinsic pathway, depending on the origin of the stimulus, can activate the caspase 
cascade. In the extrinsic pathway, extracellular signals such as tumor necrosis factors bind to 
their specific receptors on the cell membrane, triggering the oligomerization of a family of 
transmembrane adapter proteins called death proteins.1 Death adapter oligomers further 
oligomerize procaspases, leading to auto-proteolytic activation of the initiator caspase-8 (figure 
1). Activated initiator caspase cleaves and activates effector caspase-3, which activates cytokine-
activating caspases, signaling cell death (figure 1).2 On the other hand, the intrinsic pathway is 
mediated by mitochondria, which releases signaling molecules such as cytochrome c, in response 
to intracellular environment such as stress.3 The signaling molecules form the apoptosome, 
which activates initiator caspase-9 and intersects the extrinsic pathway of caspase activation to 
lead to apoptosis (figure 1).  
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Figure 1: Schematic representation of the main molecular pathways leading to apoptosis. 
In the intrinsic pathway, mitochondrial release of cytochrome c forms apoptosome and activates 
caspase 9. In the extrinsic pathway, ligand binding to specific receptors forms DISC complex, 
activating capase-8. Both pathways converge to activate caspse-3 and trigger apoptosis. 4 
Fourteen distinct caspases have been identified in mammals, eleven of which are present 
in humans5. All caspases cleave their substrates after an aspartate residue, but are divided into 
families and subgroups based on their function and the amino acid sequence of the substrates 
they recognize, respectively (figure 2). This study closely studies caspase-9, which is an initiator 
caspase, caspase-3, which is an effector caspase, and caspases- 4 and 5, which are inflammatory 
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caspases. Despite being in different functional families, caspases-4 and 5 recognize the same 
substrate as 9 and 1 (figure 2).6  
 
Figure 2: All mammalian caspases are of human origin, except for caspase-11 and 12, for 
which human counterparts do not exist. The structure of each caspase and its substrate preference 
at the P1 to P4 position are given. Caspases are also divided into families based on their 
functions.7   
Caspases are an important area of study because dysregulation of cell death leads to 
cancer, neurodegenerative disorders, and autoimmune diseases.8 Proper regulation of cell death 
and the inflammatory mechanism leading to cell death is vital for the development and 
homeostasis of living organism.  
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Sepsis 
One of the conditions caused by disruption of the homeostasis of inflammatory 
mechanism is Sepsis. Sepsis is a serious medical condition caused by an excessive immune 
response to severe infections most common in the lungs, abdomen, and urinary tract.9 It is 
common in immunocompromised individuals, elders, children, as well as in patients after 
invasive medical procedures. Even though fungi and viruses can also cause sepsis, gram-negative 
bacteria are the most common inducers.10 Over-stimulation of the inflammatory response to the 
bacteria in the blood can cause blood clots and leaky vessels, preventing the transport of 
nutrients and oxygen, thus damaging the organs.11 Sepsis affects 1.2 million people in the U.S. 
each year and costs $14.6 billion per year. It is the 10th leading cause of death in many western 
nations and the most common cause of death in the intensive care units.12  
Toll-like Receptor and Sepsis 
Toll-like Receptors (TLRs) are transmembrane proteins that recognize pathogen 
associated molecular patterns (PAMPs) such as molecular motifs conserved within microbes and 
endogenously expressed danger associated molecular pattern (DAMPs) such as heat shock 
proteins.13 TLRs combat the presence of PAMPs or DAMPs by releasing a cascade of 
inflammatory molecules, however, over-active TLRs can lead to over-inflammation resulting in 
autoimmune diseases and various forms of allergies.14 Human cells have 10 different TLRs, and 
each receptor recognizes unique molecular patterns that induce TLR specific inflammatory 
response.15Toll-like Receptor 4 (TLR4) recognizes lipopolysaccharide (LPS), present on the 
surface of gram-negative bacteria, and activates the production of inflammatory molecules 
necessary to fight off infection.16  
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The pathogenesis of sepsis has not been clearly elucidated, but the prominence of TLR4 
in sepsis propagation is well established. The usage of anti-TLR4 antibodies significantly 
increases the survival rate of mice with lethal gram-negative sepsis.17 Additionally, TLR4 
expression increases on human monocytes in volunteers undergoing LPS challenge18 and in 
patients with sepsis.19   
  Inhibitors for TLR4 such as TAK24220 and Eritoran21 exist, but they failed in phase III 
clinical trials due to lack of efficacy. This leads us to believe that other signaling pathways, in 
addition to TLRs, are also involved in sepsis propagation. 
Caspases and Sepsis 
 Normally, when LPS binds to TLR4, it activates a signaling cascade leading to 
downstream activation of transcription factor, NF-κB, 22 which up-regulates the expression of 
caspase-4.23 Recent studies have shown that LPS not only binds to TLR4 on the cell surface, but 
also enters the cytoplasm through cytoplasmic GTPase mediated lysis of pathogen containing 
vacuoles.24, 25 Once in the cytoplasm, LPS directly binds to caspase-4/5.26 This binding 
oligomerizes caspase-4 and leads to the activation of caspase-1 leading to pyroptosis.27 
Pyroptotic cell death produces inflammatory cytokines, which in the presence of high 
concentration of LPS, can surmount to be lethal. The massive host response through 
inflammatory mediators and procoagulant factors in the systemic circulation can lead to 
endothelial injury, tissue hypo-perfusion, intravascular coagulation, and refractory shock.28 The 
breakthrough that LPS directly binds to caspase-4 and induces inflammation provides reasons to 
discover inhibitors of caspase-4 that would provide protection from sepsis in the presence of 
gram-negative bacteria. 
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Nonsteroidal Anti-Inflammatory Drugs and Caspases 
Salicylic acid and salicylates, derived from nature, have long been used in medicine for 
antiseptic purposes. In 1900, aspirin was created as a more palatable form of salicylates. Since 
then, several aspirin-like drugs have been discovered and were categorized as non-steroidal anti-
inflammatory drugs (NSAIDs).29 Mechanistically, NSAIDs act by inhibiting cyclo-oxygenase-1 
(COX-1) and cyclo-oxygenase-2 (COX-2), which reduces the synthesis of prostaglandins and is 
believed to provide pain-killing and fever-reducing effects.30 In addition to aspirin, naproxen and 
ibuprofen are common NSAIDs. 
NSAIDs are effective at reducing inflammation, but are also known for having adverse 
side effects, such as gastrointestinal bleeding31 and increased risk of myocardial infarction and 
stroke.32 However, the mechanism of side effects is unknown. NSAIDs have been shown to 
increase apoptosis33 as well as inhibit cell death. Given the crucial role caspases play in cell 
death and considering that the knockout of caspase-11, the mice homologous to human caspase-
4, disrupts gastrointestinal homeostasis similar to the side effects of NSAIDs in mice,34 the 
mechanism of NSAIDs may involve caspases. While in vivo studies indicate inconclusive effects 
of NSAIDs on caspase-3 activity,35,36 in vitro experiments to study the sole interaction between 
caspases and NSAIDs have never been performed. Therefore, with the aim of elucidating the 
mechanism of the side effects of NSAIDs, the second goal of this study is to examine the direct 
interaction between NSAIDs and caspases by characterizing their specificity and IC50.   
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Summary and Objectives 
Caspases are major players of cell death. Failure to maintain homeostasis of cell death results in 
various forms of cancer and inflammatory diseases such as sepsis. With the hypothesis that 
inhibition of caspase-4 may be required to provide protection from sepsis, the first goal of this 
research is to identify and characterize novel small molecules that inhibit caspase-4. 
Additionally, given the mechanistically unexplained side effects of NSAIDs and the hypothesis 
that NSAIDs mechanism may involve caspases, the second goal of this research is to study the 
effect of NSAIDs on caspases activity by characterizing their specificity and IC50.    
Methods 
Big Picture  
The Soft Focus Protease/Kinase Library (P/K) and Prestwick Chemical Library  (FDA) of 
small molecules were screened against caspase-4 activity using a Caspase-Glo enzymatic assay 
in the University of Colorado high throughput screening facility. The compounds that reduced 
caspase-4 activity to 25% of the untreated control were considered to be top hits from each 
library. Top antagonists from each library were tested for caspase-4 specificity by performing 
Caspase-Glo enzymatic assay on caspase-3 and caspase-9. Compounds from P/K that 
specifically inhibited caspase-4 were further characterized to find the IC50 value with caspase-4. 
However, because top antagonists from FDA also happened to be NSAIDs that do not inhibit 
caspase-4 specifically, IC50 values of each NSAID with caspase-3, caspase-4, caspase-5, and 
caspase-9 were determined. In order to perform a comprehensive study of the effect of NSAIDs 
on caspases, at least one caspase from each caspase activity family was tested. While caspase-9 
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is an initiator caspase, caspase-3 is an effector caspase and caspase-4 is an inflammatory caspase. 
Additionally, caspase-4, caspase-5, and caspase-9 cleave the same substrate, thus ensuring that 
the top compounds do not also inhibit caspase-5, and caspase-9 is vital in discovering a caspase-
4 specific inhibitor. 
Expressing and Purifying Caspases 
In order to prepare for high throughput screening, specificity test, and IC50 
characterization, wild type human caspase-3, caspase-4, and caspase-9 were purified using the 
his-tag purification process; caspase-5 was bought from Enzo. A catalytically inactive caspase-4, 
with point mutation from cysteine to alanine on the 258th residue, was also purified as an 
enzymatic control as well as a control for the purification process.  
All constructs contained a C-terminal 6x His-tag, and were expressed in the E. coli strain 
BL21 pLysS using the pET expression system from Novagen. BL21 colonies carrying the 
plasmid of interest were expanded to 500 ml 2x TY culture volume, and induced to express the 
recombinant protein using IPTG. After protein expression, bacterial cells were sonicated to 
collect the lysate, which was then run through a column containing Ni+2 chelating resin. The His-
tag on the C-terminus of the protein bound to the Ni+2 beads and eluting the column with buffers 
containing 50 mM Tris.Cl, 100 mM NaCl, and up to 200 nM imidazole purified the protein 
(figure 3). SDS-PAGE, such as in figure 3, was used to verify the purification of each caspase. 
For more details, the protocol outlined by Denault and Salvesen in Expression, Purification, and 
characterization of Caspases was used to express and purify all the caspases37.  
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Figure 3: SDS-PAGE shows that 100 mM, 250 mM, and 1 M imidazole successfully 
elutes 56 kDa of mutant caspase-4 with histidine tag. 250 mM also elutes 20 kDa of activated 
caspase-4. 1) Pellet after centrifuging bacterial lysate 2) Supernatant after centrifugation 3). 
Supernatant unbound to the nickel column 4) Wash #1 of the protein-bound column 5) Wash #2 
of the protein-bound column 6) Protein elution with 10 mM Tris, 25 mM NaCl, and 50 mM 
Imidazole 7) Protein elution with 10 mM Tris, 25 mM NaCl, and 100 mM Imidazole 8) Protein 
elution with 10 mM Tris, 25 mM NaCl, and 250 mM Imidazole 9) Protein elution with 10 mM 
Tris, 25 mM NaCl, and 1 M Imidazole 
High Throughput Screening 
In order to identify caspase-4 inhibitors, the Soft Focus Protease/Kinase Library (P/K) 
containing 2500 compounds and Prestwick Chemical Library (FDA) containing 1200 
compounds were screened against caspase-4 activity. Measuring the luminescence produced in 
the Caspase-Glo assay assessed Caspase activity. In Caspase-Glo assay, a known substrate, 
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caspase-4 
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Promega CaspGlog LEHD, is added to caspase-4, which in its activated form cleaves the 
substrate and produces a molecule that luminesces in the presence of ATP and oxygen (figure 2). 
Thus, the strength of luminescence is directly proportional to the activity of the caspase.  
 
Figure 4: Mechanism of Caspase-Glo Assay: When Promega Caspase-Glo 9 LEHD 
substrate is added to caspase-9, the caspase cleaves the substrate, which reacts with ATP and 
oxygen to generate a luminescent signal. The signal emitted is proportional to the activity of the 
caspase. Although the figure is labeled caspase-9, it is also applicable to caspase-4 and caspse-5 
because they also cleave the same substrate as caspase-9. Assays with caspases that recognize 
different substrates, such as caspase-3 and caspase-7, undergo the same mechanism except the 
substrate would contain DEVD sequence instead of LEHD38.  
 
In order to ensure the activity is measured at the maximum enzyme efficiency, the 
concentration of substrate must exceed the concentration of the enzyme. The activity of 10 nM 
caspase-4 with 3 µM substrate in the presence of 30 µM of different compounds in DMSO was 
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measured on white 384-well plates. Controls of the experiment included caspase-4 with and 
without substrate and with substrate and DMSO, substrate plus buffer, pan-caspase inhibitor z-
VAD-FMK with substrate, and catalytically inactive mutant human caspase-4 with substrate. Z’ 
factor of the screen was calculated using  
  
where p stands for positive control, and n stands for negative control. Z’ factor of 0.66 indicated 
that the difference between the positive and negative control was high enough that this 
experimental setup was valid (Figure 2).  All results were duplicated and compounds that 
reduced caspase-4 activity to 25% of the activity of caspase-4 with substrate and DMSO control 
were considered top hits.  
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Figure 5: Relative luminescence units corresponding to activity of substrate plus buffer, caspase-
4 with substrate, with substrate and DMSO, with pan-caspase inhibitor z-VAD and substrate, and 
catalytically inactive mutant human caspase 4 with substrate controls. Almost 3000 fold activity 
of caspase-4 with substrate and DMSO compared to buffer, z-VAD or mutant caspase-4 controls 
determine the Z’ factor of 0.66, validating the Caspase-Glo enzymatic assay.  
Specificity Assay 
The compounds that resulted in 25% reduction of caspase-4 activity from both libraries were 
tested for their inhibition of caspase-3, caspase-4, and caspase-9. Therefore, Caspase-Glo assay 
with similar experimental setup as with caspase-4 in high throughput screening (3 µM substrate, 
10 nM caspase, and 30 µM compounds) was used to measure caspases-3 and caspase-9 
activities. The scaffold that resulted in the highest difference between caspase-4 activity and the 
activities of caspase-3 and caspase-9 was considered a specific inhibitor of caspase-4.  
IC50 
Three caspase-4-specific compounds from P/K and six compounds from FDA were tested 
to find the concentration of the compounds that would inhibit caspase activity by 50%. The P/K 
drugs shared a six-member and five-member fused heterocyclic scaffold, and demonstrated the 
most specificity for caspase-4 during initial validation. The FDA drugs were selected to represent 
a diverse class of NSAIDs with a range of potencies. The activity of caspases-3, 4, 5, and 9 in the 
presence of compound concentration ranging from 52 nM to 660 µM were tested for each 
compound to develop a full dose-response curve. In order to measure the activity during the 
maximum efficiency of each enzyme, the substrate concentration was three hundred-fold higher 
than the enzyme concentration, and the enzyme concentration was kept well below IC50.  
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In order to analyze the data, a graph of enzyme activity over time was plotted for each 
concentration. Average slope of the linear portion of the activity versus time graph was 
normalized to the average slope of DMSO control containing enzyme, substrate, and DMSO 
equal to the solvent of each drug concentration. Although higher concentrations of compounds 
were tested, the data analysis only included up to 66 µM because the DMSO control lowered 
enzyme activity beyond 66 µM, thus experiments performed wither higher concentrations were 
not valid. The normalized slope was plotted against log of compound concentration to create an 
IC50 curve. Using the equation,  
  
a four-point dose response curve was fitted on the experimental data to determine the IC50 
values as well as R-squared values. The top asymptote of the curve represents the DMSO control 
and the bottom asymptote represents the pan caspase inhibitor control. Top and bottom are fixed 
to 100% and 0, respectively. The enzyme activity in DMSO control was required to be at least 
ten-fold higher than the z-VAD control in order to consider each plate valid. The aim for each 
curve was to obtain the R-squared value greater than 0.95.   
Results 
High throughput screening 
The high throughput screening identified 75 total compounds from P/K and FDA as hits, 
which are compounds that reduced caspase-4 signal to less than 25% relative to the DMSO 
control. The entire screen had a hit rate of 2%. Figure 6 is a representative 384 well- plate for the 
high throughput screening.  
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Figure 6: A representative 384 well- plate for high throughput screening. DMSO control 
lies in column 1 while the z-VAD control is in column 24. Each well represents a compound 
tested. Compounds in red wells reduced caspase-4 activity to less than 25%, yellow wells 
reduced activity to 25%-50%, and green reduced activity to greater than 50% of DMSO control. 
All compounds were tested at 30 µM and each plate was read for 20 minutes after substrate 
addition.  
The screening of PK identified 46 hits, which were retested for caspase-4 activity and 
validated. All hits were six-member and five-member fused heterocyles containing two or more 
nitrogen heteroatom, some of which are highlighted in figure 7.    
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Figure 7: Sample structures of top hits indicate a common six-member and five-member fused 
heterocycles containing nitrogen linked to aromatic ring as a common scaffold.  
 The screening of FDA identified 26 hits, some of which were retested for caspase-4 
activity and validated. Interestingly, 7 out of top 10 high throughput screening hits and 56% of 
the total FDA hits were NSAIDs. Six different NSAIDs listed in table 1 were chosen for further 
characterization based on the wide arrays of structures and activity.  
Table 1: Summary of the structures of the six chosen NSAIDs, their inhibition mechanism, class 
of molecules, availability status, and corresponding caspase activities. All activities are results 
from the original screening data at 30 µM.  
Name Structure COX-2 
specific 
Class Availability 
Status 
Caspase-4 Activity  
 
Fenbufen 
 
yes Propionic  
Acid 
Withdrawn   ~2% 
 
Indoprofen 
 
yes Phenylpropionic 
Acid 
Withdrawn   ~5% 
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Ketorolac 
  
No Hetroaryl 
Acetic Acid 
Active in 
the US 
~5% 
 
Felbinac 
 
No Arylpropionic 
Acid 
Active in 
the US 
~9% 
 
Tiaprofenic 
Acid   
No Arylpropionic 
Acid 
Withdrawn 
in the US; 
Active in 
developing 
countries 
~5% 
 
Ketoprofen 
 
No Propionic  
Acid  
Active in 
the US 
~60% 
 
Specificity Test 
All hits from the P/K Library were tested at 30 µM for caspase-3, caspase-4, and caspase-
9 activities. In addition to having a low caspase-4 activity, a compound was considered specific 
if the caspase-4 activity was significantly lower than the activities of caspase-3 and caspase-9. 
Figure 8 shows the specificity results of the top ten compounds. Compounds 18-G9 and 25-E2 
had the highest difference in caspase activities. 22-H8 did not have high difference in caspase 
activities, but shared a similar scaffold as other two top compounds as demonstrated in figure 8. 
18-G9, 22-H8, and 25-E2 are further characterized for IC50. The compound designations arise 
from the plate and well number from the compound plates in high throughput screening.  
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Figure 8: Activity of caspase-4, 9, and 3 in the presence of top 10 hits from the P/K Library. 18-
G9 and 25-E2 were determined to be the most specific to caspase-4 based on the difference in 
activity between caspase-4 and other caspases. 22-H8 was also chosen for its similarity in 
structure with 18-G9 and 25-E2. The compound on the left is 18-G9, the middle compound is 22-
H8 and the compound on the right is 25-E2; all of the three compounds highlight a common 
scaffold. All compounds were tested at 30 µM in biological triplicates.  
Six inhibitors, which also happened to be NSAIDS, from FDA were tested for specificity 
at 30 µM. Measuring activities of caspase-3, caspase-4, and caspase-9 in the presence of six 
inhibitors (data not shown) indicate that the NSAIDs are pan-caspase inhibitors.   
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IC50  
Adam Csakai synthesized 22-H8 and IC50 of the compound with human caspase-3 and 
caspase-4 indicated that 22-H8 is not specific to caspase-4. IC50 with caspase-3 is 6306.5 ± 416.5 
nM while with caspase-4 is 2042.4 ± 351.3 nM (figure 9). 18-G9 and 25-E2 are being 
synthesized and their IC50 values are yet to be determined.  
 
Figure 9: IC50 curve of human caspase-3 and human caspase-4 in the presence of 22-H8. % 
Caspase Activity is normalized to DMSO control containing enzyme, substrate, and same 
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concentration of DMSO as the compound tested. The top asymptote, representing DMSO 
control, and the bottom asymptote, representing total inhibition by z-VAD, are fixed at 100% 
and 0%, respectively. All activities are measured in biological duplicates, each in technical 
triplicates.  
IC50 values of six NSAIDs with human caspase-3, caspase-4, caspase-5, and caspase-9 
were determined using the data in figures 10-15. All curves have an R-squared value greater than 
0.95, except for Felbinac with caspase-4 whose value is 0.917 (table 2).  The IC50 curves for 
Ketorolac (figure 10), Ketoprofen (figure 11), Fenbufen (figure 12), Indoprofen (figure 13), 
Felbinac (figure 14), and Tiaprofenic Acid (figure 15) indicated that the IC50 values of caspase-4, 
5 and 9 generally are below 2000 nM but IC50 values of caspase-3 are in the range of tens of 
thousands of nM. All NSAIDs inhibited all caspases tested.  
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Figure 10: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Ketorolac. % Caspase Activity is normalized to DMSO control 
containing enzyme, substrate, and same concentration of DMSO as the compound tested. The top 
asymptote, representing DMSO control, and the bottom asymptote, representing total inhibition 
by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in biological 
duplicates, each in technical triplicates.  
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Figure 11: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Ketoprofen. % Caspase Activity is normalized to DMSO control 
containing enzyme, substrate, and same concentration of DMSO as the compound tested. The top 
asymptote, representing DMSO control, and the bottom asymptote, representing total inhibition 
by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in biological 
duplicates, each in technical triplicates.  
 
 26 
 
Figure 12: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Fenbufen. % Caspase Activity is normalized to DMSO control 
containing enzyme, substrate, and same concentration of DMSO as the compound tested. The top 
asymptote, representing DMSO control, and the bottom asymptote, representing total inhibition 
by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in biological 
duplicates, each in technical triplicates.  
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Figure 13: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Felbinac. % Caspase Activity is normalized to DMSO control 
containing enzyme, substrate, and same concentration of DMSO as the compound tested. The top 
asymptote, representing DMSO control, and the bottom asymptote, representing total inhibition 
by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in biological 
duplicates, each in technical triplicates.  
 
 28 
 
Figure 14: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Tiaprofenic Acid. % Caspase Activity is normalized to DMSO 
control containing enzyme, substrate, and same concentration of DMSO as the compound tested. 
The top asymptote, representing DMSO control, and the bottom asymptote, representing total 
inhibition by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in 
biological duplicates, each in technical triplicates.  
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Figure 15: IC50 curve of human caspase-3, human caspase-4, human caspase-5, and human 
caspase-9 in the presence of Indoprofen. % Caspase Activity is normalized to DMSO control 
containing enzyme, substrate, and same concentration of DMSO as the compound tested. The top 
asymptote, representing DMSO control, and the bottom asymptote, representing total inhibition 
by z-VAD, are fixed at 100% and 0%, respectively. All activities are measured in biological 
duplicates, each in technical triplicates.  
Table 2: Summary of IC50 values of all six NSAIDs with caspase-3, caspase-4, caspase-5, and 
caspase-9 calculated from their four-point dose response curved as well as their R-squared values 
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indicating how well the data fits into the regression. All values are determined from biological 
duplicates, each in technical triplicates.   
Compound Caspase IC50 (nM) RSQ 
  3 2651.5	±	553.6	 0.959	
Ketorolac 4 913.5	±	55.9	 0.988	
  5 805.5	±	67.5		 0.980	
  9 612.9	±	39.8	 0.988	
3 49184.1	±	5156.2	 0.983	
4 9104.2	±	1674.1	 0.960	
5 8477.1	±	1345.3	 0.984	
Ketoprofen 9 4706.8	±	479.4	 0.992	
  3 1566.5	±	263.2	 0.98	
Fenbufen  4 621.1	±	80.9	 0.986	
  5 2200.0	±	37.9	 0.999	
  9 739.3	±	88.1	 0.966	
3 11437.7	±	1511.5		 0.957	
4 2225.4	±	428.6		 0.917	
5 1992.8	±	328.8		 0.978	
Felbinac 9 1286.2	±	66.3		 0.997	
  3 1388.8	±	145.3	 0.984	
Indoprofen 4 467.1	±	13.8	 0.998	
  5 697.8	±	71.3	 0.955	
  9 240.8	±	10.5		 0.992	
3 10995.2	±	950.6		 0.989	
4 2086.2	±	275.7		 0.972	
5 8251.3	±	91.0		 0.995	
Tiaprofenic Acid 9 1787.8	±	141.1		 0.997	
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Discussion 
Implications of P/K Library Results 
The P/K Library was screened with the purpose of discovering a novel small molecule 
that specifically inhibits caspase-4 for therapeutic purposes. 46 compounds were identified for 
reducing caspase-4 activity to less than 25% activity and all the compounds were six-member 
and five-member fused heterocycles containing two or more nitrogen linked to an aromatic ring. 
The conserved structural motifs among hits suggest consistent chemical effect and promising 
outcome of high throughput screening. 
Out of 46 compounds, only one scaffold, common in 18-G9, 22-H8, and 25-E2, was 
identified as being specific to caspase-4. The high throughput screening facility had problems 
with mis-ordered compounds that they were repeatedly freeze-thawed, which could have led to 
cross contamination or degradation. Therefore, Adam Cskai, a graduate student at the Yin Lab, 
re-synthesized the compounds to ensure the hit was as advertised and still worked.  
While 18-G9 and 25-E2 are being synthesized, IC50 characterization of 22-H8 was 
performed.  The R-squared values of 0.998 for caspase-3 and 0.978 for caspase-4 for four-point 
dose response curve indicate that 22-H8 inhibits caspase-3 in addition to caspase-4. The 
similarity in IC50 values of about 6 µM for caspase-3 and 2 µM for caspase-4 indicates that there 
will be no appreciable difference in a biological system. Even though 22-H8 is not specific to 
caspase-4, 18-G9 and 25-E2 are still promising caspase-4 specific inhibitor because unlike 22-
H8, whose caspase-3 and caspse-9 activities were less than 25% different from its caspase-4 
activity, the activities of caspase-3 and caspase-9 are more than 50% greater than caspase-4 
activity for18-G9 and 25-E2. Even though the difference between caspase-4 activity and other 
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activities was not high for 22-H8, it was chosen for IC50 analysis because it is structurally similar 
to the two most specific compounds. The fact that IC50 results indicate non-specific inhibition of 
caspase-4 with 22-H8 is consistent with the specificity results. Therefore, once they are 
synthesized, 18-G9 and 25-E2 IC50 analysis must be pursued to find a caspase-4 specific 
inhibitor.  
Implications of FDA Library Results 
In addition to finding a novel caspase-4 inhibitor, the FDA Library was screened to study 
the effect of NSAIDs on caspase activity. The results of the high throughput screening indicated 
that 56% of the top caspase-4 inhibitors and seven out of the top ten combined library hits were 
NSAIDs. IC50 characterization of six NSAIDs, chosen based on their diversity in structure and 
potency, indicated that NSAIDs are pan-caspase inhibitors. All the curves have R-squared value 
greater than 0.95, except for one outlier that lies between 0.91 and 0.95. High R-squared values 
indicate the strength with which the IC50 curves justify the experimental data points and indicate 
the confidence with which NSAIDs inhibit caspases. Interestingly, while the active sites of 
caspases are similar, the active sites of COX-1 and COX-2 are different from the active sites of 
caspases, adding to the mystery that NSAIDs are pan-caspase inhibitors.   
Among all the caspases, caspase-3 inhibition generally requires the highest concentration 
of NSAIDs and caspase-9 inhibition requires the lowest (table 2). Caspase-9 is an initiator 
caspase and appears earlier in the caspase activation pathway than other caspases tested, thus 
small amount of NSAID may be sufficient to inhibit caspase-9. That being said, caspases-4,5 and 
9 have similar IC50 values and are much lower than the value for caspase-3 for each NSAID. 
Such similarity may be explained by the fact that caspases-4, 5, and 9 share the LEHD substrate, 
indicating similarity in active sites of caspases- 4, 5, and 9 as well.  
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Based on their IC50 values, Indoprofen is the best inhibitor and Ketoprofen is the worst 
inhibitor of all the caspases tested (table 2). Coincidentally, Indoprofen was withdrawn by the 
US government for severe gastrointestinal bleeding and carcinogenicity while Ketoprofen is still 
actively available in the US despite displaying gastrointestinal upset and ulceration.39 Perhaps 
the severity of the side effect is correlated with the potency in caspase inhibition. If such is the 
case, top inhibitors of the study, Ketorolac and Felbinac, are still available in the United States 
and further study must be performed to assess their side effects. On average, patients in taking 
the recommended dosage of 10-40 mg/day have 39 µM of Ketorolac circulating in their blood. 
However, IC50 of Ketorolac is less than 1µM for caspases-4,5, and 9 and less than 3µM for 
caspase-3.40 Thus, even though in vivo values would be greater than in vitro, IC50 determined 
from this study is biologically relevant to patients using Ketorolac. Such is the case for all the 
NSAIDs tested, except for Ketoprofen, which has higher IC50 value than average concentration it 
the blood. The relevance is especially high since caspase-11, the mice homologous to human 
caspase-4, is crucial in maintaining gut homeostasis41 and the knockdown of caspase-1 enhanced 
tumor formation in a mouse model of colorectal cancer,42 both of which are also common side 
effects of NSAIDs. Thus, further studies into adjusting the recommended dosage of the drugs is 
recommended.   
Parallel experiments 
Based on the results of the in vitro experiments, caspase-1 and caspase-3 activities in cells are 
measured in the presence of the six NSAIDs. The cell culture experiments mirror the in vitro 
results, with Ketoprofen being the worst inhibitor of caspase-1 and caspase-3. IC50 
characterization of two additional NSAIDs, Ibuprofen and Naproxen, shows they also inhibit 
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caspases at lower concentration than their average circulation level. This data is performed by a 
graduate student in the Yin Lab, Tina Smith, and the results further validate and strengthen the 
conclusion that NSAIDs are pan-caspase inhibitors.  
Future Directions 
Once 18-G9 and 25-E2 are synthesized, the IC50 values of 18-G9 and 25-E2 need to be 
determined to assess whether the P/K Library contain caspase-4 specific inhibitor that could be 
used to treat sepsis. 
    This study concludes that NSAIDs are pan-caspase inhibitors in vitro, however, more 
experiments in vivo need to be performed to confirm the results and increase the relevance of the 
results presented in this study. Some ideas for future work could be using mass 
spectrophotometer to analyze the interaction between NSAIDs and the binding sites of caspases 
or using C. Elegans as a model to test the in vivo effect of NSAIDs on caspase-1 activity.  
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